Note: Data are No. (%) unless otherwise specified.
Adapted from table 2 in Lipson et al. European Journal of Cancer. 2025.

*IMAEs included AEs of any grade that occurred in at least 1 % of patients in the nivolumab plus relatlimab arm that were considered by investigators to be potentially immune-mediated and that met the following criteria: occurred within 100 days after the last dose (regardless of causality) and were treated with immune-modulating medication with no clear alternate cause or had an immune-mediated component.

^†Treatment-related deaths: Nivolumab plus relatlimab (n = 4): hemophagocytic lymphohistiocytosis, acute edema of the lung, pneumonitis, and multi-organ failure; nivolumab (n = 2): sepsis and myocarditis, and worsening pneumonia.

AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; IMAE, immune-mediated adverse event.

Reference:

1. Lipson, Evan J. et al. Nivolumab Plus Relatlimab in Advanced Melanoma: RELATIVITY-047 4-year update. Eur J Cancer. 2025 Jul 25:225:115547.